metformin has been researched along with ST Elevation Myocardial Infarction in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
ST Elevation Myocardial Infarction: A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI)." | 7.83 | Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. ( Cottin, Y; Feldman, LJ; Juliard, JM; Labalette-Bart, M; Potier, L; Roussel, R; Steg, PG; Zeller, M, 2016) |
| " (Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial; NCT01217307)." | 5.41 | Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. ( Assa, S; Connelly, MA; de Koning, MLY; Dullaart, RPF; Garcia, E; Lipsic, E; van der Harst, P; van Veldhuisen, DJ; Westenbrink, BD, 2021) |
| "Discontinuation of metformin treatment is a frequently used approach in clinical practice in diabetic ST-segment elevation myocardial infarction patients using metformin in order to reduce the risk of contrast-induced acute kidney injury." | 4.12 | Metformin and CI-AKI Risk in STEMI: Evaluation Using Propensity Score Weighting Method. ( Batgerel, U; Efe, SÇ; Kalkan, S; Karabay, CY; Karagöz, A; Kırma, C; Oduncu, V; Şimşek, B; Sungur, MA; Tanboğa, İH; Yılmaz, F; Yılmaz, MF, 2022) |
| "To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI)." | 3.83 | Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. ( Cottin, Y; Feldman, LJ; Juliard, JM; Labalette-Bart, M; Potier, L; Roussel, R; Steg, PG; Zeller, M, 2016) |
| "Between January 2011 and May 2013, 379 STEMI patients without diabetes undergoing primary percutaneous coronary intervention were randomized to a 4-month treatment with metformin (500 mg twice daily) (N = 191) or placebo (N = 188) in the University Medical Center Groningen." | 2.84 | Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT. ( Hartman, MHT; Lexis, CPH; Lipsic, E; Prins, JKB; Schurer, RAJ; van der Harst, P; van der Horst, ICC; van der Horst-Schrivers, ANA; van Veldhuisen, DJ, 2017) |
| "Metformin treatment improved diastolic function in animal models and patients with diabetes." | 2.82 | The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. ( Al Ali, L; Hartman, MT; Hummel, YM; Lexis, CP; Lipsic, E; van der Harst, P; van der Horst, IC; van Melle, JP; van Veldhuisen, DJ; Voors, AA, 2016) |
| "Metformin has been demonstrated to be beneficial for the treatment of an impaired myocardium as a result of ischemia/reperfusion (I/R) injury, and miR-34a may be involved in this process." | 1.62 | Metformin attenuates ischemia/reperfusion-induced apoptosis of cardiac cells by downregulation of p53/microRNA-34a via activation of SIRT1. ( Hao, J; Jiang, L; Jin, S; Li, W; Shi, Y, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Koning, MLY | 1 |
| Westenbrink, BD | 1 |
| Assa, S | 1 |
| Garcia, E | 1 |
| Connelly, MA | 1 |
| van Veldhuisen, DJ | 4 |
| Dullaart, RPF | 1 |
| Lipsic, E | 4 |
| van der Harst, P | 4 |
| Kalkan, S | 1 |
| Karagöz, A | 1 |
| Efe, SÇ | 1 |
| Sungur, MA | 1 |
| Şimşek, B | 1 |
| Yılmaz, MF | 1 |
| Batgerel, U | 1 |
| Yılmaz, F | 1 |
| Tanboğa, İH | 1 |
| Oduncu, V | 1 |
| Karabay, CY | 1 |
| Kırma, C | 1 |
| Yu, Q | 1 |
| Zhu, JJ | 1 |
| Liu, WX | 1 |
| Li, W | 2 |
| Jin, S | 1 |
| Hao, J | 1 |
| Shi, Y | 1 |
| Jiang, L | 1 |
| Hartman, MHT | 1 |
| Prins, JKB | 1 |
| Schurer, RAJ | 1 |
| Lexis, CPH | 1 |
| van der Horst-Schrivers, ANA | 1 |
| van der Horst, ICC | 2 |
| Hendriks, T | 1 |
| Al Ali, L | 2 |
| Maagdenberg, CG | 1 |
| van Melle, JP | 2 |
| Hummel, YM | 2 |
| Oudkerk, M | 1 |
| Nijveldt, R | 1 |
| Zeller, M | 1 |
| Labalette-Bart, M | 1 |
| Juliard, JM | 1 |
| Potier, L | 1 |
| Feldman, LJ | 1 |
| Steg, PG | 1 |
| Cottin, Y | 1 |
| Roussel, R | 1 |
| Hartman, MT | 1 |
| Lexis, CP | 1 |
| Voors, AA | 1 |
| van der Horst, IC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.[NCT01217307] | Phase 2/Phase 3 | 380 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial[NCT03980990] | Phase 4 | 500 participants (Anticipated) | Interventional | 2019-06-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months. (NCT01217307)
Timeframe: 4 months
| Intervention | % of LVEF (Mean) |
|---|---|
| Metformin | 53.1 |
| Placebo | 54.8 |
4 trials available for metformin and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction.
Topics: Aged; Biomarkers; Female; Humans; Hypoglycemic Agents; Ketone Bodies; Male; Metformin; Middle Aged; | 2021 |
Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT.
Topics: Administration, Ophthalmic; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Electrocard | 2017 |
Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction.
Topics: Cardiovascular Agents; Drug Administration Schedule; Echocardiography; Female; Heart Ventricles; Hum | 2019 |
The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction.
Topics: Aged; Diastole; Echocardiography; Female; Humans; Male; Metformin; Middle Aged; Percutaneous Coronar | 2016 |
4 other studies available for metformin and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
Metformin and CI-AKI Risk in STEMI: Evaluation Using Propensity Score Weighting Method.
Topics: Acute Kidney Injury; Contrast Media; Creatinine; Diabetes Mellitus; Humans; Metformin; Percutaneous | 2022 |
Effect of continuous use of metformin on kidney function in diabetes patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Biomarkers; Contrast Media; Creatinine; Diabetes Mellitus, Type 2; Female | 2020 |
Metformin attenuates ischemia/reperfusion-induced apoptosis of cardiac cells by downregulation of p53/microRNA-34a via activation of SIRT1.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Apoptosis; Creatine Kinase, MB Form; Down-Regul | 2021 |
Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study.
Topics: Acute Kidney Injury; Aged; Contrast Media; Coronary Angiography; Creatinine; Diabetes Mellitus, Type | 2016 |